-
-
-
-
-
-
-
Tiziana Life Sciences (TLSA) Announces Findings from Intranasal Anti-CD3 mAb Treatment
-
-
-
-
-
-
-
Tiziana Life Sciences (TLSA) to Proceed with Phase 2 Clinical of foralumab
-
-
-
-
-
-
-
Sol-Gel Technologies Ltd. (SLGL) Acquires Patidegib
-
-
-
-
-
-
-
Chemomab (CMMB) Appoints Matthew Frankel as Chief Medical Officer
-
-
-
-
-
-
-
Tiziana Life Sciences (TLSA) Announces Continued Clinical Improvements in the Second Patient with SPMS After Six Months of Dosing with Foralumab
-
-
-
-
-
-
-
Scynexis (SCYX) Reports Positive Data from Phase 3 CANDLE Nested Sub-Study Investigating Ibrexafungerp
-
-
-
-
-
-
-
Aadi Bioscience (AADI) Announces Unique Permanent J-code Issued for FYARRO by Centers for Medicare and Medicaid Services
-
717 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All